Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07237451 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients

Study acronym: CARE FOR CKD H
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Grigore T. Popa University of Medicine and Pharmacy
15 trials monitored
See 1 trial at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Heart Failure
1,995 trials monitored
See 111 trials at risk
and 1 more disease
The main aim of this study is to holistically assess the cardiovascular and renal outcomes in HFpEF CKD patients with and without SGLT2 inhibition, with focus on the endothelial disfunction, MACE and mortality using clinical evaluation, flow mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, NMR metabolomics and a series of novel biomarkers.
Trial Details
NCT Number NCT07237451
Lead Sponsor Grigore T. Popa University of Medicine and Pharmacy
Collaborators: Dr. C.I. Parhon Hospital, Iasi, The Executive Agency for Higher Education, Research, Development and Innovation Funding
Conditions
(from sponsor)		 CKD - Chronic Kidney Disease, Heart Failure Preserved Ejection Fraction, SGLT2 Inhibitors, Diabetes (DM)
Related terms Diabetes Mellitus, Heart Failure, Diastolic, Renal Insufficiency, Chronic
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov